Renal involvement in Castleman disease

Nephrology Dialysis Transplantation

Volumn 26, Issue 2, 2011, Pages 599-609

  El Karoui, Khalil ^a   Vuiblet, Vincent ^b   Dion, Daniel ^c   Izzedine, Hassan ^d   Guitard, Joelle ^e   Frimat, Luc ^f   Delahousse, Michel ^g   Remy, Philippe ^h   Boffa, Jean Jacques ⁱ   Pillebout, Evangline ^j   Galicier, Lionel ^j   Nol, Laure Hlne ^c   Daugas, Eric ^k  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL MAISON BLANCHE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e CHU RANGUEIL   (France)

^f CHU NANCY BRABOIS   (France)

^g FOCH HOSPITAL   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ HÔPITAL TENON   (France)

^j SAINT LOUIS HOSPITAL   (France)

^k BICHAT HOSPITAL   (France)

more..

Author keywords

AA amyloidosis; Castleman disease; podocyte; thrombotic microangiopathy; vascular endothelial growth factor

Indexed keywords

C REACTIVE PROTEIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADOLESCENT; ADULT; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBODY LABELING; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; GLOMERULAR DYSFUNCTION; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY DISEASE; MALE; MICROANGIOPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL ARTERY THROMBOSIS; RETICULOENDOTHELIOSIS;

ADOLESCENT; ADULT; AGED; BIOPSY; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79551498265     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq427     Document Type: Article

References (38)

1. Dham A, Peterson BA. Castleman disease. Curr Opin Hematol 2007; 14: 354-359
2. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005; 129: 3-17
3. Frizzera G, Peterson BA, Bayrd ED et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985; 3: 1202-1216
4. Rieu P, Noel LH, Droz D et al. Glomerular involvement in lymphoproliferative disorders with hyperproduction of cytokines (Castleman, POEMS). Adv Nephrol Necker Hosp 2000; 30: 305-331
5. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
6. Sartelet H, Toupance O, Lorenzato M et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5: 2441-2447
7. Bariety J, Bruneval P, Hill G et al. Posttransplantation relapse of FSGS is characterized by glomerular epithelial cell transdifferentiation. J Am Soc Nephrol 2001; 12: 261-274
8. Karie S, Izzedine H, Beaufils H et al. Lymphadenopathy and proteinuria. Nephrol Dial Transplant 2004; 19: 739-741
9. Modesto-Segonds A, Rey JP, Orfila C et al. Renal involvement in POEMS syndrome. Clin Nephrol 1995; 43: 342-345
10. Rieu P, Droz D, Gessain A et al. Retinoic acid for treatment of multicentric Castleman's disease. Lancet 1999; 354: 1262-1263
11. Nishimoto N, Sasai M, Shima Y et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95: 56-61
12. Oksenhendler E, Duarte M, Soulier J et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996; 10: 61-67
13. Maynard SE, Min JY,Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658
14. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136
15. Frangie C, Lefaucheur C, Medioni J et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8: 177-178
16. Stokes MB, Erazo MC, D'Agati VD. Glomerular disease related to anti-VEGF therapy. Kidney Int 2008; 74: 1487-1491
17. Nochy D, Lefaucheur C, Hill G. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 359: 206-207 author reply
18. Seida A, Wada J, Morita Y et al. Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury? Am J Kidney Dis 2004; 43: E3-E9
19. Nishi J, Arimura K, Utsunomiya A et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol 1999; 104: 482-485
20. Soubrier M, Sauron C, Souweine B et al. Growth factors and proinflammatory cytokines in the renal involvement of POEMS syndrome. Am J Kidney Dis 1999; 34: 633-638
21. Nishimoto N, Kanakura Y, Aozasa K et al. Humanized anti-interleukin- 6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106: 2627-2632
22. Yoshizaki K, Matsuda T, Nishimoto N et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74: 1360-1367
23. Brandt SJ, Bodine DM, Dunbar CE et al. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990; 86: 592-599
24. Suematsu S, Matsuda T, Aozasa K et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1989; 86: 7547-7551
25. Nakamoto Y, Imai H, Yasuda T et al. A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transplant 1999; 14: 2370-2378
26. Soubrier M, Deteix P, Derray G et al. Renal manifestation in POEMS syndrome. Nephrologie 1994; 15: 335-338
27. Viard JP, Lesavre P, Boitard C et al. POEMS syndrome presenting as systemic sclerosis. Clinical and pathologic study of a case with microangiopathic glomerular lesions. Am J Med 1988; 84: 524-528
28. Dispenzieri A. POEMS syndrome. Blood Rev 2007; 21: 285-299
29. Arinsoy T, Yilmaz M, Ataoglu O et al. Castleman's disease with renal amyloidosis and nephrotic syndrome. Nephrol Dial Transplant 1997; 12: 2713-2716
30. Kazes I, Deray G, Jacobs C. Castleman disease and renal amyloidosis. Ann Intern Med 1995; 122: 395-396
31. Keven K, Nergizoglu G, Ates K et al. Remission of nephrotic syndrome after removal of localized Castleman's disease. Am J Kidney Dis 2000; 35: 1207-1211
32. Saura IM, Carreton A, Lopez Guillen E et al. [A 21-year-old male patient with nephrotic syndrome and "idiopathic" AA amyloidosis]. Nefrologia 2004; 24: 109-112
33. Tanaka K, Horita M, Shibayama H et al. Secondary amyloidosis associated with Castleman's disease. Intern Med 1995; 34: 122-126
34. Lachmann HJ, Goodman HJ, Gilbertson JA et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-2371
35. Perfetti V, Bellotti V, Maggi A et al. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. Am J Hematol 1994; 46: 189-193
36. Weber J, Yang JC, Topalian SL et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993; 11: 499-506
37. Thaunat O, Delahousse M, Fakhouri F et al. Nephrotic syndrome associated with hemophagocytic syndrome. Kidney Int 2006; 69: 1892-1898
38. McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders. Hematology Am Soc Hematol Educ Program 2004; 283-296